Authors' reply to Schaffalitzky de Muckadell and colleague's Comment on "Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017".

Autor: Ehlken B; IQVIA, Landshuter Allee 10, 80637, Munich, Germany., Nathell L; Nathell Medical AB, Växthusvägen 6, 582 76, Linköping, Sweden., Gohlke A; IQVIA, Landshuter Allee 10, 80637, Munich, Germany. dr.annegret.gohlke@iqvia.com., Bocuk D; IQVIA, Landshuter Allee 10, 80637, Munich, Germany., Toussi M; IQVIA, 17 Bis Place des Reflets, TSA 64567, 92099, La Défense Cedex, France., Wohlfeil S; Vifor Pharma Management Ltd., Flughofstrasse 61, 8152, Glattbrugg, Switzerland.
Jazyk: angličtina
Zdroj: Drug safety [Drug Saf] 2019 May; Vol. 42 (5), pp. 693-696.
DOI: 10.1007/s40264-019-00815-4
Databáze: MEDLINE
Externí odkaz: